Japan Cannabinoid
Industry Weekly

March 9, 2026 ★ Site Update Business

CBD Logistics Japan Launches Fully Renewed Platform — Import Verdict™ Now Available Online

CBD Logistics Japan (Asayake Inc., Suwa City, Nagano) has launched a comprehensively renewed website at cbdlogistics.jp, introducing an online application portal for its flagship Import Verdict™ service. The renewal is timed to Japan's most significant regulatory shift in a decade — the revised Cannabis Control Act enacted December 12, 2024, which introduced product-specific Δ9-THC residue limits now actively enforced across all CBD product categories.

Import Verdict™ — Japan's only formal pre-import customs and quarantine assessment — can now be applied for entirely online. Applicants register products, upload CoA and manufacturing process documents, and receive a written verdict on importability from Japanese authorities. Starting from ¥55,000 (incl. tax) for the first product, with each additional product at ¥38,500 in the same submission.

New features include a live 2026 compliance quick reference, CBN/THC alert system, expanded service descriptions, and support for eight languages including English, Japanese, Chinese, and Korean.

📰 CBD Logistics Japan · cbdlogistics.jp — Apply for Import Verdict™ →

March 3, 2026 ⚑ Important Regulation

CBN Designation Notice Delayed Beyond February — But MHLW Intent Unchanged

Japan's Pharmaceutical & Food Safety Council ruled CBN (cannabinol) designation "appropriate" in October 2025, with a February 2026 ministerial notice expected. That notice has not been issued as of early March. However, the Ministry of Health, Labour and Welfare has confirmed its intent to proceed with designation has not changed. International brands are advised to continue treating CBN as effectively import-prohibited pending official enactment. Products with any detectable CBN level should not be submitted for MHLW import notification at this time.

📰 Ministry of Health, Labour and Welfare · mhlw.go.jp

March 1, 2026 Market

CBG Demand Among Japan Wholesale Buyers Surges as CBN Exits Market

Domestic wholesale buyers are reporting a sharp uptick in CBG (cannabigerol) inquiries following CBN's effective market exit. Currently unscheduled under Japanese pharmaceutical law, CBG is being positioned by several brands as the primary replacement for the sleep-support and relaxation market previously served by CBN products. Industry observers note that MHLW has not yet initiated formal review of CBG, though informally the compound is being monitored. Early entry with proper compliance documentation is likely to confer first-mover advantage.

📰 CBD Japan · cbdjapan.com

February 25, 2026 Science

Japan-Accredited Labs Update CBN Detection Limits — Sub-0.1 ppm Now Achievable

Multiple Japanese-accredited analytical laboratories have updated their CBN limit of detection (LOD) to sub-0.1 ppm levels following instrument upgrades. This means import screening may effectively require a "CBN not detected" standard rather than a numeric threshold. Exporters whose products were previously borderline-compliant should re-test with the updated detection methods before submitting any new MHLW import documentation. Confirm the specific detection capabilities of your testing lab before proceeding.

📰 Industry intelligence · 株式会社あさやけ research

February 27, 2026 ⚑ Important Regulation

Tokyo Metropolitan Police Department Issues Warning on Illegal Delta-8 THC Products

Tokyo Metropolitan Police Department issued a public warning regarding the sale of delta-8 THC products through domestic e-commerce channels. Several online retailers have been identified as selling products containing delta-8 THC, which is considered a controlled substance under the revised Cannabis Control Act. The warning signals escalating enforcement intent and should be noted by any brand involved in the Japanese CBD market, particularly those whose product lines include any isomerized THC compounds.

📰 Tokyo Metropolitan Police Department

February 25, 2026 Market

Japan CBD Market Estimated at ¥36 Billion for FY2025 — Growth Despite Regulatory Tightening

A market research firm released its FY2025 estimate for Japan's CBD market at approximately ¥36 billion (approx. USD 240M), representing modest growth despite the regulatory changes introduced in December 2024. Analysts attribute resilience to strong consumer demand for wellness products and the consolidation of market share among compliant brands following enforcement actions against non-compliant competitors. Premium positioning and documented compliance are increasingly cited as key purchase drivers among Japanese consumers.

📰 Yano Research Institute

February 24, 2026 Science

Tohoku University Study Finds No Cognitive Impairment at Therapeutic CBD Doses in Rodent Models

A peer-reviewed study from Tohoku University published in a Japanese pharmacology journal found no cognitive impairment in rodent models at doses equivalent to therapeutic human CBD consumption. The study adds to a growing Japanese academic literature on cannabinoid safety, which is increasingly cited by industry groups in regulatory discussions with MHLW. While not directly impacting current import rules, favorable domestic research is considered strategically important for the long-term regulatory trajectory of CBD in Japan.

📰 Japanese Journal of Pharmacology

February 24, 2026 Business

European CBD Brand Secures Distribution Deal with Japanese Natural Products Distributor

A European CBD isolate brand announced a distribution agreement with a Tokyo-based natural products wholesaler specializing in imported wellness products. The brand cited completion of Japan's MHLW import notification process and a full Japan-accredited lab CoA as prerequisites that made the deal possible. The announcement is notable as an example of a compliant market entry pathway and underscores the value of regulatory preparation as a commercial enabler, not merely a legal obligation.

📰 Nutraceuticals World Japan

February 19, 2026 ⚑ Important Regulation

MHLW Publishes Guidance on Water-Soluble CBD Product Classification

The Ministry of Health, Labour and Welfare issued clarifying guidance on the classification of water-soluble CBD preparations for import assessment purposes. The guidance reaffirms that the 0.1 ppm THC residue limit — not the 10 ppm limit applicable to oils — applies to any CBD product intended for dilution in water, including water-soluble powders, emulsified concentrates, and beverage premixes. This is one of the most commonly misapplied aspects of Japan's December 2024 residue rules and has resulted in multiple failed import attempts by international brands.

📰 MHLW · mhlw.go.jp

February 18, 2026 Market

Major Japanese Drugstore Chain Revises CBD Policy Following Compliance Review

One of Japan's top-five drugstore chains has revised its internal CBD product procurement policy following an internal compliance review. The chain will now require all CBD product suppliers to provide a current Japan-accredited lab CoA dated within 12 months and written confirmation from the importer that MHLW import notification has been filed. The move is expected to influence other major retail chains to implement similar supplier requirements, raising the compliance bar across the domestic distribution channel.

📰 Nikkei MJ (Retail Edition)

February 17, 2026 Business

Canadian Hemp Exporter Halts Japan Shipments Amid CBN Re-Testing Requirements

A Canadian hemp extract exporter has voluntarily suspended Japan-bound shipments following an internal audit revealing that several product lines contained CBN at levels that may not pass Japan's updated import screening. The company cited the need for re-formulation and re-testing at a Japan-accredited laboratory before resuming exports. The case illustrates a challenge facing broad-spectrum product exporters: CBN contamination from the natural hemp extraction process often requires dedicated remediation steps that many exporters had not previously budgeted for.

📰 Canadian Hemp Trade Alliance